A Study of PVX-410 a Cancer Vaccine and Citarinostat +/- Lenalidomide for Smoldering MM
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma.
The following intervention will be involved in this study:
- Citarinostat (CC-96241)
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma
- ClinicalTrials.gov Identifier: NCT02886065
- Protocol Number: 16-237
- Principal Investigator: David Avigan
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required